UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Comparison of Performance of the IRI 2016, IRI‐Plas 2017, and NeQuick 2 Models During Different Solar Activity (2013–2018) Years Over South American Sector

Radio science, 2020-08, Vol.55 (8), p.n/a

Tariku, Yekoye Asmare

2020

Volltextzugriff (PDF)

Antibiotic use in patients with COVID-19: a ‘snapshot’ Infectious Diseases International Research Initiative (ID-IRI) survey

Journal of antimicrobial chemotherapy, 2020-11, Vol.75 (11), p.3386-3390

2020

Volltextzugriff (PDF)

IRI the International Standard for the Ionosphere

Advances in radio science, 2018-09, Vol.16, p.1-11

Bilitza, Dieter

2018

Volltextzugriff (PDF)

Recent Approaches to Targeting Canonical NF κ B Signaling in the Early Inflammatory Response to Renal IRI

Journal of the American Society of Nephrology, 2021-09, Vol.32 (9), p.2117-2124

2021

Volltextzugriff (PDF)

Adaboost Algorithm in Artificial Intelligence for Optimizing the IRI Prediction Accuracy of Asphalt Concrete Pavement

Sensors (Basel, Switzerland), 2021-08, Vol.21 (17), p.5682

2021

Volltextzugriff (PDF)

Comparison of GPS TEC with modelled values from IRI 2016 and IRI-PLAS over Istanbul, Turkey

Astrophysics and space science, 2018-11, Vol.363 (11), p.1-9, Article 231

Atıcı, Ramazan

2018

Volltextzugriff (PDF)

Suppressing succinate accumulation during ischemia protects the kidney from IRI

Kidney international, 2023-10, Vol.104 (4), p.646-649

2023

Volltextzugriff (PDF)

Performance of IRI 2016 model in predicting total electron content (TEC) compared with GPS-TEC over East Africa during 2019-2021

Scientific reports, 2024-05, Vol.14 (1), p.10010-10010, Article 10010

Sulungu, Emmanuel D

2024

Volltextzugriff (PDF)

Assimilation of GIRO data into a real-time IRI

Radio science, 2012-08, Vol.47 (4), p.n/a

2012

Volltextzugriff (PDF)

Obesity Aggravates Ischemia-Reperfusion Injury (IRI)-Induced AKI in Mice: SA-PO072

Journal of the American Society of Nephrology, 2022-11, Vol.33 (11S), p.621-621

2022

Volltextzugriff (PDF)

Results of a phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma (NEO-Nal-IRI study)

Journal of clinical oncology, 2024-01, Vol.42 (3_suppl), p.655-655

2024

Volltextzugriff (PDF)

Effects of Sevoflurane on Apoptosis of Myocardial Cells in IRI Rats

BioMed research international, 2021, Vol.2021 (1), p.3347949-3347949

2021

Volltextzugriff (PDF)

Randomized phase II study of nalicap (nal-IRI/capecitabine) compared to NAPOLI (nal-IRI/5-FU/LV) in gemcitabine-pretreated advanced pancreatic cancer: Trial-in-progress

Journal of clinical oncology, 2022-02, Vol.40 (4_suppl), p.TPS621-TPS621

2022

Volltextzugriff (PDF)

Evaluating F2-region long-term trends using the International Reference Ionosphere (IRI) model: is this a feasible approximation for experimental trends?

Atmospheric chemistry and physics, 2023-11, Vol.23 (21), p.13973-13986

2023

Volltextzugriff (PDF)

Development and validation of the Illness Representation Interview (IRI)

European psychiatry, 2024-08, Vol.67 (S1), p.S97-S98

2024

Volltextzugriff (PDF)

A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma: NEO-Nal-IRI study

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS4190-TPS4190

2023

Volltextzugriff (PDF)

Do irinotecan (IRI) dose reductions driven by UGT1A128 genotyping prevent IRI-related severe neutropenia? A real-world study

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e16116-e16116

2020

Volltextzugriff (PDF)

Regorafenib (REG) combined with irinotecan (IRI) versus IRI alone as second-line treatment in patients with metastatic gastro-oesophageal adenocarcinomas (mGA): A randomized phase II trial (PRODIGE 58 – UCGI 35 – REGIRI)

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.387-387

2023

Volltextzugriff (PDF)

1838P Do irinotecan (IRI) dose reductions driven by UGT1A128 genotyping prevent IRI-related severe neutropenia? A real-world study

Annals of oncology, 2020-09, Vol.31, p.S1056-S1056

2020

Volltextzugriff (PDF)

A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma (NEO-Nal-IRI Study)

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.TPS778-TPS778

2023

Volltextzugriff (PDF)

Predicting IRI Using Machine Learning Techniques

International journal of pavement research & technology, 2023-01, Vol.16 (1), p.128-137

2023

Volltextzugriff (PDF)

WJOG6510G: Randomized phase II of Pmab + IRI vs Cmab + IRI for KRAS WT mCRC previously treated after FU, IRI, and L-OHP

Annals of oncology, 2017-10, Vol.28 Suppl 9, p.ix74

2017

Volltextzugriff (PDF)

Clinical Benefit of Bevacizumab and Irinotecan (BEV+IRI) in Patients With Relapsed/Refractory Glioblastoma (r/rGBM) and its Potential Predictors

Anticancer research, 2022-12, Vol.42 (12), p.6091-6098

2022

Volltextzugriff (PDF)

The Limits of Empirical Electron Density Modeling: Examining the Capacity of E‐CHAIM and the IRI for Modeling Intermediate (1‐ to 30‐Day) Timescales at High Latitudes

Radio science, 2020-04, Vol.55 (4), p.n/a

2020

Volltextzugriff (PDF)

A phase II, open-label, pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma: NEO-Nal-IRI study

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS4196-TPS4196

2022

Volltextzugriff (PDF)

1 – 25 von 38.859

Suche als RSS-Feed

Aktive Filter

ThemaInternal Medicine

ThemaMarketing

ThemaMiddle Aged

KollektionEZB Free E-Journals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(31.493)
Mit Volltextzugriff
(36.762)

Publikationsform

5 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(32.779)
Japanisch
(4.618)
Portugiesisch
(2.544)
Türkisch
(1.728)
Spanisch
(1.358)
Deutsch
(383)
Latein
(313)
Französisch
(309)
Croatian
(206)
Rumänisch
(157)
Slowenisch
(152)
Niederländisch
(139)
Chinesisch
(91)
Litauisch
(64)
Russisch
(57)
Koreanisch
(56)
Italienisch
(55)
Norwegisch
(53)
Polnisch
(49)
Tschechisch
(37)

15 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(18.931)
Life Sciences & Biomedicine
(11.248)
Physical Sciences
(5.554)
Animals
(4.194)
Humans
(4.110)
Technology
(3.184)
Science & Technology - Other Topics
(2.634)
Male
(2.590)
Ischemia
(2.412)
Multidisciplinary Sciences
(2.266)
Chemistry
(1.809)
Proteins
(1.634)
Apoptosis
(1.614)
Engineering
(1.589)
Inflammation
(1.587)
Review
(1.561)
Mice
(1.521)
Analysis
(1.479)
Female
(1.433)
Reperfusion
(1.402)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

EZB Electronic Journals Library
(38.859)
IngentaConnect Journals
(14.476)
IngentaConnect Journals
(12.199)
MEDLINE
(7.303)
WK Lippincott Williams & Wilkins–Connect here FIRST to enable access
(4.692)
Publisher website
(3.914)
JSTOR
(3.658)
Wiley Online Library - AutoHoldings Journals
(2.890)
Springer Online Journals
(2.631)
Springer Nature - Connect here FIRST to enable access
(2.013)
Wiley Online Library Full Collection 2018
(1.932)
EBSCOhost Business Source Ultimate
(1.537)
Nexis Uni
(1.113)
Access via ScienceDirect (Elsevier)
(1.053)
Taylor & Francis Journals Auto-Holdings Collection
(912)
SAGE Publications
(732)
Sociological Abstracts
(681)
Taylor & Francis Journals Complete
(635)
Access via Oxford University Press
(635)
Worldwide Political Science Abstracts
(560)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Plos One
(635)
糖尿病
(634)
Scientific Reports
(608)
International Journal Of Molecular Sciences
(511)
Nature Communications
(494)
Journal Of The Japan Diabetes Society
(370)
Radio Science
(338)
Mnemosyne
(313)
Tonyōbyō
(309)
Diabetes
(304)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Comparison of Performance of the IRI 2016, IRI‐Plas 2017, and NeQuick 2 Models During Different Solar Activity (2013–2018) Years Over South American Sector

Antibiotic use in patients with COVID-19: a ‘snapshot’ Infectious Diseases International Research Initiative (ID-IRI) survey

IRI the International Standard for the Ionosphere

Recent Approaches to Targeting Canonical NF κ B Signaling in the Early Inflammatory Response to Renal IRI

Adaboost Algorithm in Artificial Intelligence for Optimizing the IRI Prediction Accuracy of Asphalt Concrete Pavement

Comparison of GPS TEC with modelled values from IRI 2016 and IRI-PLAS over Istanbul, Turkey

Suppressing succinate accumulation during ischemia protects the kidney from IRI

Performance of IRI 2016 model in predicting total electron content (TEC) compared with GPS-TEC over East Africa during 2019-2021

Assimilation of GIRO data into a real-time IRI

Obesity Aggravates Ischemia-Reperfusion Injury (IRI)-Induced AKI in Mice: SA-PO072

Results of a phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma (NEO-Nal-IRI study)

Effects of Sevoflurane on Apoptosis of Myocardial Cells in IRI Rats

Randomized phase II study of nalicap (nal-IRI/capecitabine) compared to NAPOLI (nal-IRI/5-FU/LV) in gemcitabine-pretreated advanced pancreatic cancer: Trial-in-progress

Evaluating F2-region long-term trends using the International Reference Ionosphere (IRI) model: is this a feasible approximation for experimental trends?

Development and validation of the Illness Representation Interview (IRI)

A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma: NEO-Nal-IRI study

Do irinotecan (IRI) dose reductions driven by UGT1A128 genotyping prevent IRI-related severe neutropenia? A real-world study

Regorafenib (REG) combined with irinotecan (IRI) versus IRI alone as second-line treatment in patients with metastatic gastro-oesophageal adenocarcinomas (mGA): A randomized phase II trial (PRODIGE 58 – UCGI 35 – REGIRI)

1838P Do irinotecan (IRI) dose reductions driven by UGT1A128 genotyping prevent IRI-related severe neutropenia? A real-world study

A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma (NEO-Nal-IRI Study)

Predicting IRI Using Machine Learning Techniques

WJOG6510G: Randomized phase II of Pmab + IRI vs Cmab + IRI for KRAS WT mCRC previously treated after FU, IRI, and L-OHP

Clinical Benefit of Bevacizumab and Irinotecan (BEV+IRI) in Patients With Relapsed/Refractory Glioblastoma (r/rGBM) and its Potential Predictors

The Limits of Empirical Electron Density Modeling: Examining the Capacity of E‐CHAIM and the IRI for Modeling Intermediate (1‐ to 30‐Day) Timescales at High Latitudes

A phase II, open-label, pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma: NEO-Nal-IRI study

Aktive Filter

Suchergebnisse filtern